MAIA on NYSE

MAIA Biotechnology, Inc.

American pharmaceutical preparations company based in Chicago. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerMAIA on NYSE1
  • IndustryPharmaceutical Preparations1
  • HeadquartersChicago, Illinois1
  • Incorporated inDE2
  • Business address444 West Lake Street, Suite 1700, Chicago, Il 606062
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

The patients received either 60mg, 180mg, or 360mg of ateganosine per dose, and 42 had at least one post baseline assessment completed.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-639.8%Return on equity4

Financial statements

Revenue567$0 in 2024
02022: $0$020222023: $0$020232024: $0$02024
Operating income5674-$17.0M in 2024+118% since 2021
-$30.0M-$20.0M-$10.0M02021: -$7.8M-$7.8M20212022: -$16.2M-$16.2M2022+108%2023: -$20.2M-$20.2M2023+25%2024: -$17.0M-$17.0M2024−16%
Net income5674-$23.3M in 2024+85% since 2021
-$30.0M-$20.0M-$10.0M02021: -$12.6M-$12.6M20212022: -$15.8M-$15.8M2022+25%2023: -$19.8M-$19.8M2023+25%2024: -$23.3M-$23.3M2024+18%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Research and development expenses$14.5M$10.0M
General and administrative expenses$9.7M$6.9M
Total operating expenses$24.3M$17.0M
Loss from operations-$24.3M-$17.0M
Interest expense-$57
Interest income$314.0K$318.4K
Australian research and development incentives$80.0K
Grant income$361.4K
Change in fair value of warrant liability$1.2M-$6.7M
Loss on fair value of warrants over proceeds-$13.0K
Other income (expense) net:$1.9M-$6.3M
Net loss-$22.4M-$23.3M
Net loss per share - basic-$0.70-$1.05
Net loss per share - diluted-$0.70-$1.05
Weighted average common shares outstanding - basic32.1M shares22.2M shares
Weighted average common shares outstanding - diluted32.1M shares22.2M shares

Compare MAIA Biotechnology, Inc. with another company

Leadership

Who has led MAIA Biotechnology, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Vlad Vitoc2022–now

Chief financial officer

  1. Joseph F. McGuire2022–2023
2025
Board members and other officers (11)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorLouie Ngar Yee named Nov 12, 2024 to Jan 5, 202622

Timeline

  1. Jul 27, 2022New chief executive Vlad Vitoc becomes CEO10

Filings

503 filings to the SEC since October 2021: 4 annual reports, 14 quarterly reports, 110 major events, 248 insider forms, 12 large holders, 7 private raises, 108 other. The latest 20:

  1. Oct 7, 2026424B3 EDGAR
  2. Oct 6, 2026EFFECT EDGAR
  3. Oct 6, 20268-K EDGAR
  4. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  5. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  6. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  7. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  8. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  9. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  10. Oct 2, 2026424B3 EDGAR
  11. Sep 25, 2026S-3 EDGAR
  12. Sep 15, 20264 PRIMARY DOCUMENT EDGAR
  13. Sep 14, 20264 PRIMARY DOCUMENT EDGAR
  14. Sep 1, 20264 PRIMARY DOCUMENT EDGAR
  15. Aug 28, 2026EFFECT EDGAR
  16. Aug 26, 20264 PRIMARY DOCUMENT EDGAR
  17. Aug 24, 20264 PRIMARY DOCUMENT EDGAR
  18. Aug 21, 2026S-3 EDGAR
  19. Aug 14, 2026SCHEDULE 13G/A EDGAR
  20. Aug 10, 202610-Q EDGAR

The 503 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

145 open-market trades by officers, directors and large owners since October 2021: 145 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 14, 2026Vitoc VladChief Executive OfficerBuy73,000$1.37$100.0KForm 4
Sep 10, 2026Guerrero RamiroDirectorBuy37,595$1.32$49.6KForm 4
Aug 28, 2026Guerrero RamiroDirectorBuy46,620$1.35$62.9KForm 4
Aug 27, 2026Guerrero RamiroDirectorBuy78,239$1.39$108.8KForm 4
Aug 26, 2026Guerrero RamiroDirectorBuy8,931$1.39$12.4KForm 4
Aug 24, 2026Guerrero RamiroDirectorBuy1,794$1.33$2.4KForm 4
Aug 20, 2026Guerrero RamiroDirectorBuy11,899$1.37$16.3KForm 4
Jun 1, 2026Vitoc VladChief Executive OfficerBuy72,700$1.39$101.1KForm 4
Jun 1, 2026Smith StanDirectorBuy75,000$1.34$100.5KForm 4
Jun 1, 2026Gryaznov SergeiChief Scientific OfficerBuy2,000$1.35$2.7KForm 4
Dec 22, 2025Smith StanDirectorBuy57,189$1.22$69.8KForm 4
Dec 22, 2025CHAOUKI STEVEN MDirectorBuy40,849$1.22$49.8KForm 4
Dec 22, 2025Louie Ngar YeeDirectorBuy81,699$1.22$99.7KForm 4
Dec 5, 2025Smith StanDirectorBuy13,740$1.20$16.4KForm 4
Nov 28, 2025Vitoc VladChief Executive OfficerBuy50,000$1.14$57.0KForm 4
Nov 28, 2025Vitoc VladChief Executive OfficerBuy50,000$1.14$57.0KForm 4
Nov 28, 2025Luput CristianDirectorBuy18,145$1.11$20.1KForm 4
Nov 26, 2025Vitoc VladChief Executive OfficerBuy22,000$1.05$23.1KForm 4
Nov 26, 2025Vitoc VladChief Executive OfficerBuy22,000$1.05$23.1KForm 4
Nov 26, 2025Luput CristianDirectorBuy20,000$1.08$21.6KForm 4

All 145 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 22, 2025Raised $1.5 million in a private offering of equity Form D: $2 million offered in all Form D
  2. Sep 29, 2025Raised $3 million in a private offering of equity Form D: $7 million offered in all Form D
  3. May 28, 2025Raised $694,998 in a private offering of equity Form D: $8 million offered in all Form D
  4. Feb 18, 2025Raised $4.1 million in a private offering of equity Form D: $5.9 million offered in all Form D
  5. Oct 28, 2024Raised $2.4 million in a private offering of equity Form D: $15.5 million offered in all Form D
  6. Mar 11, 2024Raised $2.9 million in a private offering of equity Form D: $5.7 million offered in all Form D
  7. Nov 15, 2023Raised $4.9 million in a private offering of equity Form D: 3 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 36. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Solas Capital Management, LLC3,030,845$4.4M2.3%−1,266,159
Alyeska Investment Group, L.P.2,500,000$3.6M0.0%No change
Vanguard Capital Management LLC2,413,270$3.5M0.0%+339,225
683 Capital Management, LLC1,066,666$1.5M0.1%No change
Centric Wealth Management796,723$1.1M0.2%No change
Cable Car Capital, LP514,583$741.0K0.0%−133,920
Geode Capital Management, LLC504,380$726.6K0.0%+143,899
Bleichroeder LP500,000$720.0K0.1%No change
Renaissance Technologies LLC415,700$598.6K0.0%New
BlackRock, Inc.403,011$580.3K0.0%+275,033
Vanguard Fiduciary Trust Co336,688$484.8K0.0%+137,374
State Street Corp201,750$290.5K0.0%+62,800
Bleakley Financial Group, LLC181,623$261.5K0.0%New
Northern Trust Corp125,171$180.2K0.0%+72,632
Morgan Stanley104,017$149.8K0.0%+90,158
Bridgeway Capital Management, LLC76,000$109.4K0.0%+40,000
Two Sigma Investments, LP50,383$72.6K0.0%New
Envestnet Asset Management Inc44,347$63.9K0.0%New
Susquehanna International Group, Llp35,223$50.7K0.0%New
Pvg Asset Management Corp34,135$49.2K0.0%No change
UBS Group AG33,435$48.1K0.0%−18,482
Citadel Advisors LLC24,890$35.8K0.0%New
Cetera Investment Advisers22,748$32.8K0.0%New
Lazari Capital Management, Inc.21,750$31.3K0.0%New
Atria Investments, Inc21,100$30.4K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28